{"id":390332,"date":"2019-11-11T00:00:00","date_gmt":"2019-11-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0001-2019-biopharma-alzheimers-disease-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-04-24T11:28:06","modified_gmt":"2026-04-24T11:28:06","slug":"dlsfcg0001-2019-biopharma-alzheimers-disease-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0001-2019-biopharma-alzheimers-disease-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Alzheimer&#8217;s Disease | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>The Alzheimer\u2019s disease (<abbr title=\"Alzheimer's disease\">AD<\/abbr>) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives\u2014in particular, disease-modifying therapies (<abbr title=\"disease-modifying therapy\">DMT<\/abbr>s) that can slow the course of the disease. In response, drug developers\u2014from big pharma to small biotech\u2014continue to invest heavily in disease-modifying approaches due to the tremendous clinical and commercial opportunity in this arena, despite decades of late-phase failures. While, many uncertainties remain about the approval prospects for aducanumab, and the fate of anti-amyloid MAbs from Biogen \/ Eisai (BAN2401) and Roche (gantenerumab) in their ongoing Phase III trials,\u00a0key opinion leaders (<abbr title=\"key opinion leader\">KOL<\/abbr>s) are cautiously optimistic about the anti-tau therapies (approximately 15) in early- to mid-phase trials, and hope remains for the late-phase therapies from Lundbeck \/ Otsuka, Avanir \/ Otsuka, and Acadia that are in development for the treatment of\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>\u00a0agitation and psychosis, respectively. Ultimately, however, the launch of any of these is far from guaranteed.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>What are the drivers and constraints in the\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>\u00a0market?<\/li>\n<li>How large is the treatable\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>\u00a0population? What commercial uptake can be expected from Rexulti, AVP-786, and Nuplazid should they launch?<\/li>\n<li>What will be the impact of\u00a0<abbr title=\"disease-modifying therapy\">DMT<\/abbr>s\u2014should any of them launch\u2014on diagnosis, drug treatment, and revenue, and which populations will be most affected?<\/li>\n<li>What are the key learning points from the recent failure of late-phase anti-amyloid therapies, and what are experts\u2019 opinions of the launch prospects for agents still in development, such as Biogen \/ Eisai\u2019s BAN2401?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390332","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390332\/revisions"}],"predecessor-version":[{"id":576590,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390332\/revisions\/576590"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}